. 2012 May 2;8(2):103–110. doi: 10.1007/s11420-012-9275-y

Table 3.

The progression of bone turnover markers over the course of 2 years

Patient	Bone-specific alkaline phosphatase (mcg/L)			N-Telopeptide crosslinks (nmol BCE/mmol Cr)			Overall follow-up (months)
Patient	Baseline	3–8 months	1–2 years	Baseline	3–8 months	1–2 years	Overall follow-up (months)
1^a	6.1	–	N/A	11	16	N/A	12
2	10.7	12.1	11.5	15	48	45	14
3	11.1	–	16	23	49	25	26
4	3.9	12.6	N/A	19	17	N/A	6
5^b	11.4	12.1	12.5	46	102	75	12
6	5.2	10	10	19	36	30	26
7^a	8.1	–	N/A	22	18	N/A	10
8^b	12.9	–	15.7	52	26	25	36
9	14.1	–	–	28	70	49	36
10^b	–	–	12.1	–	29	38	24

^aPatients did not receive teriparatide treatment

^bThese patients had contralateral complete atypical femoral fracture, which can increase the level of bone turnover markers

N/A not applicable